Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis
With PD-1/PD-L1 inhibitors, PD-L1 positive CC patients demonstrate superior ORR, DCR, median PFS, and median OS, underscoring PD-L1 as one biomarker for immunotherapy response.
Authors
- Jie Yang (ORCID: https://orcid.org/0000-0001-7358-4586)
- Qiming Wang (ORCID: https://orcid.org/0000-0002-7813-2885)
- Mingli Zhu (ORCID: https://orcid.org/0000-0002-6758-2274)
- Yilei Zhang (ORCID: https://orcid.org/0000-0003-1407-0301)
- Haizan Yu
- Mengyu Zhang
Institutions
- Ningbo University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.3389/fonc.2024.1454372
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70